Fig 1: Elevated TRIP6 expression is associated with poor prognosis in human breast cancer patients. a Real-time PCR and western blot analysis of TRIP6 expression in immortalized human breast epithelial cell line (MCF-10a) and five breast cancer cell lines. b Real-time PCR and western blot analysis of TRIP6 expression in six matched breast cancer tissues (T) and adjacent noncancerous tissues (ANT). TRIP6 mRNA levels were normalized to that of GAPDH. TRIP6 protein levels were normalized to GAPDH. c The expression of TRIP6 in normal breast tissues and breast cancer tissues at different clinical stages. d Kaplan–Meier survival analysis of the correlation between TRIP6 expression level and 5-year OS in breast cancer patients. e Relapse-free survival (RFS) of breast cancer patients with low versus high TRIP6 expression. f Kaplan–Meier analysis of the RFS in breast cancer using Kaplan–Meier Plotter (http://kmplot.com/analysis/)
Fig 2: TRIP6 enhances the stemness of breast cancer cells. a GSEA indicated significant correlations between TRIP6 mRNA expression and stemness-related gene signatures (WONG_EMBRYONIC_STEM_CELL, BHATTACHARYA_ EMBRYONIC_ STEM_CELL). b Real-time PCR and Western blot analysis of stemness-related markers in the indicated cells. Error bars represent the mean ± SD of three independent experiments; *P < 0.05. c Representative micrographs (left) and quantification (right) of mammosphere formation by TRIP6-transduced cells, TRIP6-silenced cells and vector cells. Error bars represent the mean ± SD of three independent experiments; *P < 0.05. d Real-time PCR of the mRNA expression of cancer stem cell markers. Error bars indicate the mean ± SD of three independent experiments; *P < 0.05. e TRIP6 expression levels significantly correlated with CD44 expression in breast cancer tissues (n = 340; P < 0.01). Two representative cases are shown (left) and percentage of specimens with low or high TRIP6 expression, relative to the levels of CD44 staining (right)
Fig 3: TRIP6 promotes the proliferation and tumorigenicity of breast cancer cells. a Confirmation of the overexpression and knockdown of TRIP6 in ZR-75-30 and MDA-MB-231 cells; GAPDH was used as a loading control. b, c MTT and colony formation assays indicated that the growth rates increased in TRIP6-transduced breast cancer cells and decreased in TRIP6-silenced breast cancer cells. The number of colonies was quantified in the colony formation assay. Error bars represent the mean ± SD of three independent experiments. *P < 0.05. d ZR-75-30 cells with overexpression of TRIP6 and silencing TRIP6 were inoculated into the fat pad (n = 5/group) of mice. A representative image of each group of mouse tumors (left). Indicates the tumor volume growth curve (center) and average tumor weight (right) of the tumor formed by the indicated cells. Error bars represents the mean ± SD. *P < 0.01
Fig 4: Mechanism of TRIP6-mediated expansion of cancer stem-like cells. a GSEA showed the positive correlations between TRIP6 mRNA levels and Wnt/β-catenin-activated gene signatures (HALLMARK_WNT_BETA_CATENIN_SIGNALING and PID_WNT_CANONICAL_PATHWAY) and β-catenin nucleus gene signature (PID_BETA_CATENIN_NUC_PATHWAY). b The cellular protein levels of p-GSK3β (Ser9), GSK3β, p-β-catenin (Y142) and β-catenin in indicated ZR-75-30 and MDA-MB-231 cells were detected by Western blotting assay. GAPDH was used as the cellular control. c Luciferase-reporter assays of TOP/FOP transcriptional activity in the indicated cells. Error bars represent the mean ± SD of three independent experiments; *P < 0.05. d Western blot analysis of β-catenin in the nuclear fractions of the indicated cells. e Immunofluorescence staining showed the localization of β-catenin in the indicated cells. f Representative images and quantification of cellular spheres formed by the indicated cells. Error bars represent the mean ± SD of three independent experiments; *P < 0.05
Fig 5: Silencing of TRIP6 inhibited CRC cell proliferation, invasion, and migration and promoted apoptosis. A TRIP6 expression was increased to various degrees in CRC cell lines and NCM460 cells. B Western blotting and RT‒qPCR analyses of TRIP6 expression in LoVo cells transfected with sh-TRIP6 or sh-RNA. C The cell proliferation rate after TRIP6 knockdown was determined via CCK-8 assays. D The effect of TRIP6 knockdown on LoVo cell proliferation was demonstrated via EdU assays. E Colony formation ability of TRIP6-knockdown cells. F Wound-healing assays showed decreased migration of LoVo cells transfected with sh-TRIP6. G The migration of TRIP6-knockdown cells was measured via Transwell assays. H The invasion of TRIP6-knockdown cells was assessed via Transwell assays. I, J Flow cytometric analysis and quantitative analysis showing cell cycle progression and cell death of LoVo cells transfected with sh-TRIP6. **P < 0.01, ***P < 0.001, ****P < 0.0001
Supplier Page from Abcam for Anti-TRIP6 antibody